Phospholipase A2 isoforms as novel targets for prevention and treatment of inflammatory and oncologic diseases

Current Drug Targets

Volumn 17, Issue 16, 2016, Pages 1940-1962

  Yarla, Nagendra Sastry ^a   Bishayee, Anupam ^b   Vadlakonda, Lakshmipathi ^c,d   Chintala, Ramakrishna ^a   Duddukuri, Govinda Rao ^a   Reddanna, Pallu ^d   Dowluru, Kaladhar S V G K ^a,e  

^a GITAM UNIVERSITY   (India)

^b Larkin Health Science Institute   (United States)

^c KAKATIYA UNIVERSITY   (India)

^d UNIVERSITY OF HYDERABAD   (India)

^e Bilaspur Vishwavidyalaya   (India)

Author keywords

Cancer; Inflammation; Phospholipase A2; PLA2 isoform specific inhibitors

Indexed keywords

ARACHIDONIC ACID; ARISTOLOCHIC ACID; BETA GLUCURONIDASE; CYCLOOXYGENASE 1; ELLAGIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLAVONOID; G PROTEIN COUPLED RECEPTOR; ICOSANOID; IMMUNOGLOBULIN E; INTERLEUKIN 1; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; LIPOXYGENASE; LYSOPHOSPHOLIPID; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE A2; PLATELET DERIVED GROWTH FACTOR; QUERCETIN; RUTOSIDE; SILIBININ; SPHINGOSINE 1 PHOSPHATE; TUMOR NECROSIS FACTOR; UROCORTIN; ISOPROTEIN; PHOSPHOLIPASE A2 INHIBITOR;

ADULT RESPIRATORY DISTRESS SYNDROME; ANGIOGENESIS; CARDIOVASCULAR DISEASE; CELL DEATH; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; GLIOBLASTOMA; HUMAN; INFLAMMATORY DISEASE; INTRAVASCULAR ULTRASOUND; MALIGNANT NEOPLASM; MASS SPECTROMETRY; METASTASIS; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; X RAY CRYSTALLOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; ENZYME ACTIVE SITE; INFLAMMATION; METABOLISM; MOLECULAR MODEL; MOLECULARLY TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

ANIMALS; CATALYTIC DOMAIN; HUMANS; INFLAMMATION; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHOSPHOLIPASE A2 INHIBITORS; PHOSPHOLIPASES A2; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION;

EID: 85015680446     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666150727122501     Document Type: Review

References (229)

1. Cuendet M, Pezzuto JM. The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabol Drug Interact 2000; 17: 109-57.
2. Karin M, Dieter S, Ewgenij P. Inhibitors of the arachidonic acid cascade: Interfering with multiple pathways. Basic Clin Pharmacol Toxicol 2014; 114: 83-91.
3. Takiko D, Susanne T, Irina NT, et al. Cyclooxygenase-1 is overex-pressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res 2006; 66: 2527-531.
4. Cianchi F, Cortesini C, Magnelli L, et al. Inhibition of 5- lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol Cancer Ther 2006; 5: 2716-26.
5. Kit YC, Khalit M, Audrey JAO, Zamrie, I, Lip YC. Bioactivity-guided fractionation of the lipoxygenase and cyclooxygenase inhibiting constituents from Chisocheton polyandrus Merr. Fitoterapia 2012; 83: 961-7.
6. Hudson N, Balsitis M, Everitt S, Hawkey CJ. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993; 34: 742-7.
7. Martel PJ, Lajeunesse D, Reboul P, Pelletier JP. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2003; 62: 501-9.
8. Tavolari S, Bonafè M, Marini M, Ferreri C, Bartolini G, Brighenti E. Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Carcinogenesis 2008; 29: 371-80.
9. Ganesh R, Marks DJ, Sales K, Winslet MC, Seifalian AM. Cy-clooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal cancer cells. World J Surg Oncol 2012; 10: 200.
10. Mai S, Saki K, Chika H, et al. Arachidonic acid and cancer risk: a systematic review of observational studies. BMC Cancer 2012; 12: 606.
11. Xu Y, Fang XJ, Casey G, Mills GB. Lysophospholipids activate ovarian and breast cancer cells. Biochem J 1995; 309: 933-40.
12. John EB, Edward AD. Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res 2009; 50: S237-S242.
13. Dennis EA, Cao J, Hsu YH, Magrioti V, Kokotos G. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev 2011; 111: 6130-85.
14. Qu, X.D.; Lehrer, R.L. Secretory phospholipase A2 is the principal bactericide for staphylococci and other gram-positive bacteria in human tears. Infect Immun 1998; 66: 2791-7.
15. Mitsuishi, M.; Masuda, S.; Kudo, I.; Murakami, M. Group V and X secretory phospholipase A2 prevents adenoviral infection in mammalian cells. Biochem J 2006; 393: 97-106.
16. Balestrieri B, Hsu VW, Gilbert H, et al. Group V secretory phospholipase A2 translocates to the phagosome after zymosan stimulation of mouse peritoneal macrophages and regulates phagocytosis. J Biol Chem 2006; 281: 6691-8.
17. Balestrieri B, Maekawa A, Xing W, Gelb MH, Katz HR, Arm JP. Group V secretory phospholipase A2 modulates phagosome maturation and regulates the innate immune response against Candida albicans. J Immunol 2009; 182: 4891-8.
18. Boilard E, Lai Y, Larabee K, et al. A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis. EMBO Mol Med 2010; 2: 172-87.
19. Nevalainen TJ, Haapamäki MM, Grönroos JM. Roles of secretory phospholipases A(2) in inflammatory diseases and trauma. Biochim Biophys Acta 2000; 1488: 83-90.
20. Jia JH, Gang T, Ning Z. Cytosolic phospholipase A2 and its role in cancer. Clin Oncol Cancer Res 2011; 8: 71-76.
21. Yasuhito S, Jesu´s B, Edward AD. Localization and functional interrelationships among cytosolic Group IV, secreted Group V, and Ca2+-independent Group VI phospholipase A2s in P388D1 macrophages using GFP/RFP constructs. Biochimica et Biophysica Acta, 2005; 1735: 119-29.
22. Kono N, Inoue T, Yoshida Y, et al., Protection against oxidative stress-induced hepatic injury by intracellular type II platelet-activating factor acetylhydrolase by metabolism of oxidized phos-pholipids in vivo. J Biol Chem 2008; 283: 1628-36.
23. Atsushi M, Kenji H, Junken A, Hiroyuki A, Keizo I. Protection against oxidative stress-induced cell death by intracellular platelet-activating factor-acetylhydrolase II. J Biol Chem 1997; 272: 32315-20.
24. Verheij HM, Slotboom AJ, De Haas GH. Structure and function of phospholipase A2. Rev Physiol Biochem Pharmacol 1981; 91: 91-203.
25. Burke JE, Karbarz MJ, Deems RA, Li S, Woods VL, Dennis EA. Interaction of n group IA phospholipase A2 with metal ions and phospholipid vesicles probed with deuterium exchange mass spectrometry. Biochemistry 2008; 47: 6451-9.
26. Dennis EA. Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem 1994; 269(18): 13057-60.
27. Scott DL, White SP, Otwinowski Z, Yuan W, Gelb MH, Sigler PB. Interfacial catalysis: the mechanism of phospholipase A2. Science 1990; 250: 1541-6.
28. Berg OG, Gelb MH, Tsai MD, Jain MK. Interfacial enzymology: the secreted phospholipase A(2)-paradigm. Chem Rev 2001; 101: 2613-54.
29. Dessen A, Tang J, Schmidt H, et al. Crystal structure of human cytosolic phospholipase A2 reveals a novel topology and catalytic mechanism. Cell 1999; 97: 349-60.
30. Park JB, Lee CS, Jang JH, et al. Phospholipase signalling networks in cancer. Nat Rev Cancer 2012; 12: 782-92.
31. Lio YC, Dennis EA. Interfacial activation, lysophospholipase and transacylase activity of group VI Ca2+-independent phospholipase A2. Biochim Biophys Acta 1998; 1392: 320-32.
32. Winstead MV, Balsinde J, Dennis EA Calcium-independent phospholipase A(2): structure and function. Biochim Biophys Acta 2000; 1488: 28-39.
33. Samanta U, Bahnson BJ. Crystal structure of human plasma platelet-activating factor acetylhydrolase: structural implication to lipoprotein binding and catalysis. J Biol Chem 2008; 283: 31617-24.
34. Tjoelker LW, Wilder C, Eberhardt C, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995; 374(6522): 549-53.
35. Tselepis AD, Karabina SA, Stengel D, Piédagnel R, Chapman MJ, Ninio E. N-linked glycosylation of macrophage-derived PAF-AH is a major determinant of enzyme association with plasma HDL. J Lipid Res 2001; 42: 1645-54.
36. Glukhova A, Hinkovska-Galcheva V, Kelly R, Abe A, Shayman JA, Tesmer JJ. Structure and function of lysosomal phospholipase A2 and lecithin:cholesterol a cyltransferase. Nat Commun 2015; 6: 6250.
37. Hiraoka M, Abe A, Shayman JA. Structure and function of lysosomal phospholipase A2: identification of the catalytic triad and the role of cysteine residues. J Lipid Res 2005; 46: 2441-7.
38. Uyama T, Morishita J, Jin XH, Okamoto Y, Tsuboi K, Ueda N. The tumor suppressor gene H-Rev107 functions as a novel Ca2+-independent cytosolic phospholipase A1/2 of the thiol hydrolase type. J Lipid Res 2009; 50(4): 685-93.
39. 2 containing a Cys-His-His catalytic triad. J Biol Chem 2012; 287: 35260-74.
40. 2, enabling it to extract, bind, and hydrolyze phospholipid substrates. Proc Natl Acad Sci USA 2015; 112: E516-25.
41. Nhat DQ, Robert DA, Brian SC. Secretory phospholipase A2 enzymes as pharmacological targets for treatment of diseases. Biochem Pharmacol 2014; 90: 338-48.
42. 2α activity that is responsible for arachidonic acid release. J Biol Chem 2003; 278: 24153-63.
43. Lagarde M. Biosynthesis and functions of eicosanoids. Recent data. C R Seances Soc Biol Fil 1995; 1189: 839-51.
44. Fonteh AN, Atsumi G, LaPorte T, Chilton FH. Secretory phospholipase A2 receptor-mediated activation of cytosolic phospholipase A2 in murine bone marrow-derived mast cells. J Immunol 2000; 165: 2773-82.
45. Yu JA, Kalatardi S, Dohse J, et al. Group IIa sPLA2 inhibition attenuates NF-kappaB activity and promotes apoptosis of lung cancer cells. Anticancer Res 2012; 32: 3601-3607.
46. Vindrieux D, Augert A, Girard CA. PLA2R1 mediates tumor suppression by activating JAK2. Cancer Res 2013; 73: 6334-45.
47. Augert A, Payre C, de Launoit Y, Gil J, Lambeau G, Bernard D. The M-type receptor PLA2R regulates senescence through the p53 pathway. EMBO Rep 2009; 10: 271-7.
48. Chakraborti S. Phospholipase A2 isoforms: a perspective. Cell Signal 2003; 15: 637-65.
49. Edwards SH, Thompson D, Baker SF, Wood SP, Wilton DC. The crystal structure of the H48Q active site mutant of human group IIA secreted phospholipase A2 at 1.5 A resolution provides an insight into the catalytic mechanism. Biochemistry 2002; 41: 15468-76.
50. Ravaux L, Denoyelle C, Monne C, Limon I, Raymondjean M, El HK. Inhibition of interleukin-1beta-induced group IIA secretory phospholipase A2 expression by peroxisome proliferator-activated receptors (PPARs) in rat vascular smooth muscle cells: cooperation between PPARbeta and the protooncogene BCL-6. Mol Cell Biol 2007; 27: 8374-87.
51. Valentin E, Singer AG, Ghomashchi F, Lazdunski M, Gelb MH, Lambeau G. Cloning and recombinant expression of human group IIF-secreted phospholipase A(2). Biochem Biophys Res Commun 2000; 279: 223-8.
52. Dong Z,, Meller J, Succop P, et al. Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells. Int J Oncol 2014; 45: 978-84.
53. Hernández M, Martin R, Garcia-Cubillas MD, Maeso-Hernández P, Nieto ML. Secreted PLA2 induces proliferation in astrocytoma through the EGF receptor: another inflammation-cancer link. Neuro-Oncol. 2010; 12: 1014-23.
54. Linkous AG, Yazlovitskaya EM, Hallahan DE. Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis. J Natl Cancer Inst 2010; 102: 1398-412.
55. Gorovetz M, Schwob OM, Yedgar S, Reich R. MMP production in human fibrosarcoma cells and their invasiveness are regulated by group IB secretory phospholipase A2 receptor-mediated activation of cytosolic phospholipase A2. Front Biosci 2008; 13: 1917-25.
56. Tay A, Simon JS, Squire J, Hamel K, Jacob HJ, Skorecki K. Cytosolic phospholipase A2 gene in human and rat: chromosomal localization and polymorphic markers. Genomics 1995; 26: 138-41.
57. Govianna T, Marta S, Ombretta S. Cytosolic PLA2α and cancer: A role in tumor angiogenesis. J Natl Cancer Inst 2010; 102: 1377-9.
58. D'Orazi G, Sciulli MG, Di SV, et al. Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells. Clin Cancer Res. 2006; 12: 735-41.
59. Makoto M, Yoshihito N, Hiroshi K, Ichiro K. Cellular components that functionally interact with signaling phospholipase A2s. Biochimica et Biophysica Acta 2000; 1488; 159-66.
60. 2 in cell growth and signaling. Biochem Pharmacol 2008; 76: 1059-67.
61. Hai YQ, James HS. Toll-like receptor 4 signaling regulates cytosolic phospholipase A2 activation and lipid generation in lipopoly-saccharide-stimulated macrophages. J Biol Chem, 2005; 280: 38969-75.
62. 2pathway in the regulation of platelet apoptosis induced by ABT-737 and strong platelet agonists. Cell Death Dis 2013; 4: e931.
63. Haripriya S, Bryan, NK, Janani P, Parth L, Soochong K, Satya, PK. G-protein-gated inwardly rectifying potassium channels regulates ADP-induced cPLA2 activity in platelets through Src family kinases. Blood 2006; 108: 3027-34.
64. Gong, P.; Angelini, D.J.; Yang, S. et al. TLR4 signaling is coupled to SRC family kinase activation, tyrosine phosphorylation of zonula adherens proteins, and opening of the paracellular pathway in human lung microvascular endothelia. J Biol Chem 2008; 283: 13437-49.
65. Pindado J, Balsinde J, Balboa MA. TLR3-dependent induction of nitric oxide synthase in RAW 264.7 macrophage-like cells via a cytosolic phospholipase A2/cyclooxygenase-2 pathway. J Immunol 2007; 179: 4821-8.
66. Yang CM, Lee IT, Chi PL, Cheng SE, Hsiao LD, Hsu CK. TNF-α induces cytosolic phospholipase A2 expression via Jak2/PDGFR-dependent Elk-1/p300 activation in human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2014; 306: L543-L551.
67. Lee IT, Lin CC, Cheng SE, Hsiao LD, Hsiao YC, Yang CM. TNF-α induces cytosolic phospholipase A2 expression in human lung epithelial cells via JNK1/2- and p38 MAPK-dependent AP-1 activation. PLoS One 2013; 8: e72783.
68. Luo SF, Lin, CC, Chen HC, et al. Involvement of MAPKs, NF-kappaB and p300 co-activator in IL-1beta-induced cytosolic phospholipase A2 expression in canine tracheal smooth muscle cells. Toxicol Appl Pharmacol 2008; 232: 396-407.
69. Margot, C.L.; Esma, I. Interleukin-1β regulation of inducible nitric oxide synthase and cyclooxygenase-2 involves the p42/44 and p38MAPK signaling pathways in cardiac myocytes. Hypertension 1999; 33: 276-82.
70. Angelo, YM, Nilda, MM, Lucille, NM, et al. Cytosolic group IVa phospholipase A2 mediates IL-8/CXCL8-induced transmigration of human polymorphonuclear leukocytes in vitro. J Inflamm 2010; 7: 14.
71. Keith BG, Peter V. Phospholipase A2 in clinical inflammation-molecular approaches to pathophysiology. CRC press, Francis and Taylor group 1995. ISBN 9780849385445. p100.
72. Kwon JH, Lee JH, Kim KS, Chung YW, Kim IY. Regulation of cytosolic phospholipase A2 phosphorylation by proteolytic cleavage of annexin A1 in activated mast cells. J Immunol 2012; 188: 5665-73.
73. Samuelsson B. An elucidation of the arachidonic acid cascade. Discovery of prostaglandins, thromboxane and leukotrienes. Drugs 1987; 33: 2-9.
74. Li-Yuan C, Grzegorz W, Sahrudaya N, Carolea L, James HS. Cytosolic phospholipase A2 activation induced by S1P is mediated by the S1P3 receptor in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2008; 295: L326-L335.
75. Isenović ER, Kedees MH, Tepavčević S, et al. Role of PI3K/AKT, cPLA2 and ERK1/2 signaling pathways in insulin regulation of vascular smooth muscle cells proliferation. Cardiovasc Hematol Disord Drug Targets 2009; 9: 172-80.
76. Yellaturu CR, Rao GN. Cytosolic phospholipase A2 is an effector of Jak/STAT signaling and is involved in platelet-derived growth factor BB-induced growth in vascular smooth muscle cells. J Biol Chem 2003; 278: 9986-92.
77. Zhu C, Sun Z, Li C, Guo R, Li L, Jin L, Wan R, Li, S. Urocortin affects migration of hepatic cancer cell lines via differential regulation of cPLA2 and iPLA2. Cell Signal 2014; 26: 1125-34.
78. Cheng SE, Lin CC, Lee IT, Hsu CK, Kou YR, Yang CM. Cigarette smoke extract regulates cytosolic phospholipase A2 expression via NADPH oxidase/MAPKs/AP-1 and p300 in human tracheal smooth muscle cells. J Cell Biochem 2011; 112: 589-99.
79. Seilhamer JJ, Pruzanski W, Vadas P, et al. Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. J Biol Chem 1989; 264: 5335-8.
80. Hegen M, Sun L, Uozumi N, et al. Cytosolic phospholipase A2alpha-deficient mice are resistant to collagen-induced arthritis. J Exp Med 2003; 197: 1297-302.
81. Henderson WR Jr, Chi EY, Bollinger JG, et al. Importance of group X-secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model. J Exp Med 2007; 204: 865-77.
82. Minami T, Tojo H, Shinomura Y, Matsuzawa Y, Okamoto M. Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis. Gut 1994; 35: 1593-8.
83. Pruzanski W, Lee P, Stefanski E, Sternby B, Vadas P. Hypophos-pholipasemia A2 in systemic sclerosis. J Rheumatol 1990; 17: 1182-6.
84. Stefanski E, Pruzanski W, Sternby B, Vadas P. Purification of soluble phospholipaseA2 from synovial fluid in rheumatoid arthritis. J Biochem 1986; 100: 1297-303.
85. Groeneveld AB, Raijmakers PG, Rauwerda JA, Hack CE. The inflammatory response to vascular surgery-associated ischaemia and reperfusion in man: effect on postoperative pulmonary function. Eur J Vasc Endovasc Surg 1997; 14: 351-9.
86. Aufenanger J, Samman M, Quintel M, Fassbender K, Zimmer W, Bertsch T. Pancreatic phospholipase A2 activity in acute pancreatitis: a prognostic marker for early identification of patients at risk. Clin Chem Lab Med 2002; 40: 293-7.
87. Zhang KJ, Zhang DL, Jiao XL, Dong C. Effect of phospholipase A2 silencing on acute experimental pancreatitis. Eur Rev Med Pharmacol Sci 2013; 17: 3279-84.
88. Timo JN. Serum phospholipases A2 in inflammatory diseases. Clinical Chem 1993; 39: 2453-9.
89. Touqui L, Wu YZ. Interaction of secreted phospholipase A2 and pulmonary surfactant and its pathophysiological relevance in acute respiratory distress syndrome. Acta Pharmacol Sin 2003; 24: 1292-6.
90. Curfs DM, Ghesquiere SA, Vergouwe MN, et al. Macrophage secretory Phospholipase A2 group X enhances anti-inflammatory responses, promotes lipid accumulation, and contributes to aberrant lung pathology. J Biol Chem 2008; 283: 21640-8.
91. Ohtsuki M, Taketomi Y, Arata S, et al., Transgenic expression of group V, but not group X, secreted phospholipase A2 in mice leads to neonatal lethality because of lung dysfunction. J Biol Chem 2006; 281: 36420-33.
92. Triggiani M, Giannattasio G, Calabrese C. et al. Lung mast cells are a source of secreted phospholipases A2. J Allergy Clin Immunol 2009; 124: 558-65.
93. Hallstrand TS, Lai Y, Ni, Z, et al. Relationship between levels of secreted phospholipase A₂ groups IIA and X in the airways and asthma severity. Clin Exp Allergy 2011; 41: 801-10.
94. Nilda MM, Angelo YM, Jonathan PA, Joseph VB, Wonhwa C, Alan RL. Deletion of secretory group V phospholipase A2 attenuates cell migration and airway hyperresponsiveness in immunosen-sitized mice. J Immunol 2007; 179: 4800-7.
95. Ewa P, Rafal P. The involvement of phospholipases A2 in asthma and chronic obstructive pulmonary disease. Mediators Inflam 2013; 12.
96. 2α for the treatment of asthma. JPET, 2012; 340: 656-65.
97. Rosenson RS, Gelb MH Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes. Curr Cardiol Rep 2009; 11: 445.
98. Ivandic B, Castellani, LW, Wang, XP, et al. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogene-sis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. J. Arterioscler Thromb Vasc Biol 1999; 19: 1284-90.
99. Zhang H, Zhang J, Shen D, et al. Lentiviral-mediated RNA interference of lipoprotein-associated phospholipase A2 ameliorates inflammation and atherosclerosis in apolipoprotein E-deficient mice. Int J Mol Med 2013; 31: 651-9.
100. 2 Inhibitors for the Reduction of Cardiovascular Events. Cardiol Ther 2013; 2: 125-34.
101. Scott KF, Sajinovic M, Hein J, et al. Emerging roles for phospholipase A2 enzymes in cancer. Biochimie 2010; 92: 601-10.
102. Jiazhong J, Blake LN, Jeremy R, et al. Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Pathol 2002; 160: 667-71.
103. Matsuda Y, Ogawa M, Sakamoto K, et al. Development of a radio-immunoassay for human group II phospholipase A2 and demonstration of postoperative elevation. Enzyme 1991; 45: 200-8.
104. Yamashita S, Yamashita J, Ogawa M. Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency. Br J Cancer 1994; 69: 1166-70.
105. Yu JA, Mauchley D, Li, H, et al. Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo. J Thorac Cardiovasc Surg 2012; 144: 1185-91.
106. Eiji K, Noriko H, Keiji H, Goro K, Masanori S. Activation of MAP kinase cascade induced by human pancreatic phospholipase A2 in a human pancreatic cancer cell line. FEBS Lett 1997; 407: 343-6.
107. 2 in human lung cancer cells. Ann Thorac Surg 2014; 98: 439-45.
108. Buhmeida A, Bendardaf R, Hilska M, et al. PLA2 (group IIA phospholipase A2) as a prognostic determinant in stage II colorectal carcinoma. Ann Oncol 2009; 20: 1230-5.
109. Vesna B, Gerard L, Toni P. Secreted phospholipases A2 in cancer: Diverse mechanisms of action. Biochimie 2014; 107: 114-23.
110. Ganesan K, Ivanova T, Wu Y, et al. Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Cancer Res 2008; 68: 4277-86.
111. Xing XF, Li H, Zhong XY, et al. Phospholipase A2 group IIA expression correlates with prolonged survival in gastric cancer. Histopathology 2011; 59: 198-206.
112. Wang X, Huang CJ, Yu GZ, et al. Expression of group IIA phospholipase A2 is an independent predictor of favorable outcome for patients with gastric cancer. Hum Pathol 2013; 44(10): 2020-7.
113. Leung SY, Chen X, Chu KM, et al. Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc Natl Acad Sci USA 2002; 99(25): 16203-8.
114. Cormier RT, Hong KH, Halberg RB, et al. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat Genet 1997; 17: 88-91.
115. Fijneman RJ, Bade LK, Peham JR, et al. Pla2g2a attenuates colon tumorigenesis in azoxymethane-treated C57BL/6 mice; expression studies reveal Pla2g2a target genes and pathways. Cell Oncol 2009; 31: 345-56.
116. Laye JP, Gill JH. Phospholipase A2 expression in tumours: a target for therapeutic intervention? Drug Discov Today 2003; 8: 710-6.
117. 2): Targeting cancer through the ablation of tumor vascu-lature. Clin Cancer Res 2009; 15: 1635-44.
118. Takaku K, Sonoshita M, Sasaki N. Suppression of intestinal polyposis in Apc(delta 716) knockout mice by an additional mutation in the cytosolic phospholipase A(2) gene. J Biol Chem 2000; 275: 34013-6.
119. Hong KH, Bonventre JC, O’Leary E, Bonventre JV, Lander ES. Deletion of cytosolic phospholipase A(2) suppresses Apc(Min)-induced tumorigenesis. Proc Natl Acad Sci USA 2001; 98: 3935-9.
120. Sundarraj S, Kannan S, Thangam R, Gunasekaran P. Effects of the inhibition of cytosolic phospholipase A(2)α in non-small cell lung cancer cells. J Cancer Res Clin Oncol 2012; 138: 827-35.
121. Meyer AM, Dwyer-Nield LD. Hurteau GJ, et al. Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2. Carcinogenesis 2004; 25: 1517-24.
122. Ilsley JN, Nakanishi M, Flynn C, et al. Cytoplasmic phospholipase A2 deletion enhances colon tumorigenesis. Cancer Res 2005; 65: 2636-43.
123. Mary CM, Weiser E, Xue QW, et al. Depletion of cytosolic phospholipase A2 in bone marrow-derived macrophages protects against lung cancer progression and metastasis. Cancer Res. 2009; 69: 1733-8.
124. 2 metabolites play a critical role in pulmonary tumor metastasis in mice. Anticancer Res 2010; 30: 3421-7.
125. Ribatti D, Nico B, Crivellato E. The role of pericytes in angiogenesis. Int J Dev Biol 2011; 55: 261-8.
126. Herbert SP, Odell AF, Ponnambalam S, Walker JH. Activation of cytosolic phospholipase A2-{alpha} as a novel mechanism regulating endothelial cell cycle progression and angiogenesis. J Biol Chem 2009; 284: 5784-96.
127. Durham JT, Surks HK, Dulmovits BM, Herman IM. Pericyte con-tractility controls endothelial cell cycle progression and sprouting: insights into angiogenic switch mechanics. Am J Physiol Cell Physiol 2014; 307: C878-92.
128. Carmelina DA, Gabriella L, Loriana R, et al. Endothelial cell-pericyte cocultures induce PLA2 protein expression through activation of PKCa and theMAPK/ERK cascade. J Lipid Res 2007; 48: 783-93.
129. Giovanna T, Marta S, Ombretta S. Cytosolic phospholipase A2α and cancer: A role in tumor angiogenesis. J Natl Cancer Inst 2010; 102: 1377-9.
130. Waeber C, Blondeau N, Salomone S. Vascular sphingosine-1-phosphate S1P1 and S1P3 receptors. Drug News Perspect 2004; 17: 365-82.
131. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005; 97: 512-23.
132. Anfuso CD, Motta C, Giurdanella G, Arena V, Alberghina M, Lupo G. Endothelial PKCα-MAPK/ERK-phospholipase A2 pathway activation as a response of glioma in a triple culture model. A new role for pericytes? Biochimie 2014; 99: 77-87.
133. McHowat J, Gullickson G, Hoover RG, Sharma, J, Turk J, Korn-bluth J. Platelet-activating factor and metastasis: calcium-independent phospholipase A2β deficiency protects against breast cancer metastasis to the lung. Am J Physiol Cell Physiol 2011; 300: C825-32.
134. Hiraoka M, Abe A, Lu Y, et al. Lysosomal phospholipase A2 and phospholipidosis. Mol Cell Biol 2006; 26: 6139-6148.
135. Guardia T, Rotelli AE, Juarez AO, Pelzer LE. Anti-inflammatory properties of plant flavonoids. Effects of rutin, quercetin and hesperidin on adjuvant arthritis in rat. Farmaco 2001; 56: 683-7.
136. Lindahl M, Tagesson C. Flavonoids as phospholipase A2 inhibitors: importance of their structure for selective inhibition of group II phospholipase A2. Inflammation 1997; 21: 347-56.
137. Hongyan C, Qing M, Miao G, et al. Anti-tumor effect of rutin on human neuroblastoma cell lines through inducing G2/M cell cycle arrest and promoting apoptosis. Sci World J 2013; 8.
138. Lindahl, M, Tagesson C. Selective inhibition of group II phospholipase A2 by quercetin. Inflammation 1993; 17: 573-82.
139. Manthey JA, Guthrie N, Grohmann K. Biological Properties of Citrus Flavonoids Pertaining to Cancer and Inflammation. Curr Med Chem 2001; 8: 135-53.
140. Zheng SY, Li Y, Jiang D, Zhao J, Ge JF. Anticancer effect and apoptosis induction by quercetin in the human lung cancer cell line A-549. Mol Med Rep 2012; 5: 822-6.
141. 2 by extracts from native and genetically modified Eclipta alba: Isolation of active coumestans. Basic Clin Pharmacol Toxicol 2009; 104: 293-9.
142. Sivalokanathan S, Subhash CG, Jagadananda G. Wedelolactone, a medicinal plant-derived coumestan, induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt. Int J Oncol 2012; 41: 2191-9.
143. Pereañez, J.A.; Patiño, A.C.; Núñez, V.; Osorio, E. The biflavonoid morelloflavone inhibits the enzymatic and biological activities of a snake venom phospholipase A2. Chem Biol Interact 2014; 220C: 94-101.
144. Gil B, Sanz MJ, Terencio, M.C, Gunasegaran R, Payá M,. Alcaraz MJ. Morelloflavone, a novel biflavonoid inhibitor of human secretory phospholipase A2 with anti-inflammatory activity. Biochem Pharmacol 1997; 53: 733-40.
145. Pang X, Yi T, Yi Z, et al. Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways. Cancer Res 2009; 69: 518-25.
146. Decha P, Nongporn HT. Morelloflavone, a biflavonoid inhibitor of migration-related kinases, ameliorates atherosclerosis in mice. Am J Physiol Heart Circ Physiol 2012; 302: H451-8.
147. Hagelgans A, Nacke B, Zamaraeva M, Siegert G, Menschikowski M. Silibinin down-regulates expression of secreted phospholipase A2 enzymes in cancer cells. Anticancer Res 2014; 34: 1723-9.
148. Mastron JK, Siveen KS, Sethi G, Bishayee A. Silymarin and hepatocellular carcinoma: a systematic, comprehensive, and critical review. Anti-cancer Drugs 2015; 26: 475-86.
149. Tyagi AK, Agarwal C, Chan DC, Agarwal R. Synergistic anticancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep 2004; 11: 493-9.
150. 2 activity. Toxicon 2008; 52: 655-66.
151. Miriam DR, Vishwanath BS, Richard CF. Effects of aristolochic acid on phospholipase A2 activity and arachidonate metabolism of human neutrophils. Toxicon 1987; 25: 939-46.
152. Mor MCN, Bettina M, Ruppelt P, Nuno AP. Plant natural products active against snake bite-the molecular approach. Walter B. Phyto-chemistry 2000; 55: 627-42.
153. Vishwanath, BS, Appu, RAG, Gowda TV. Interaction of phospholipase A2 from Vipera russelli venom with aristolochic acid: a circular dichroism study. Toxicon 1987; 25: 939-46.
154. Chandra V, Jasti J, Kaur P, Srinivasan A, Betzel Ch, Singh TP. Structural basis of phospholipase A2 inhibition for the synthesis of prostaglandins by the plant alkaloid aristolochic acid from a 1.7 A crystal structure. Biochemistry 2002; 41(36): 10914-9.
155. Moreno JJ. Effect of aristolochic acid on arachidonic acid cascade and in vivo models of inflammation. Immunopharmacol 1993; 26: 1-9.
156. Mariappan S. Therapeutic efficiency of aristolochic acid on oral cancer induced experimental rats. IOSR J Pharm Biol Sci 2012; 4: 12-20.
157. 2 synthase without affecting cyclooxygenase-1 activity: Different mechanisms of action are involved in the inhibition of platelet aggregation and macrophage inflammatory response. Nutrients 2014; 6: 3336-52.
158. th September, 2014; pp. 43.
159. Durvasula VRV, Nagendra SY, Parimi U. Synthesis, of novel piperine analogs of dipeptidyl boronic acid as antimicrobial and anticancer agents. Med Chem 2014; 4: 9.
160. Yi L, Jianping X, Hehe L, Lu L, Lei P. Piperine induces apoptosis of lung cancer A549 cells via p53-dependent mitochondrial signaling pathway. Tumor Biol 2014; 35: 3305-10.
161. Keith B, Robert SJ. Molecular pharmacology of manoalide: Inactivation of bee venom phospholipase A2. Biochem Pharmacol 1986; 35: 449-53.
162. 2 activity by manoalide associated with inactivation of crotoxin toxicity and dissociation of the heterodimeric neurotoxic complex. Biochem Pharmacol 2002; 63: 755-61.
163. Kobayashi M, Okamoto T, Hayashi K, Yokoyama N, Sasaki T, Kitagawa I. Marine natural products. XXXII. Absolute configurations of C-4 of the manoalide family, biologically active sesterter-penes from the marine sponge Hyrtios erecta Chem Pharm Bull 1994; 42: 265-70.
164. Lister MD, Glaser KB, Ulevitch RJ, Dennis EA. Inhibition studies on the membrane-associated phospholipase A2 in vitro and prostaglandin E2 production in vivo of the macrophage-like P388D1 cell. Effects of manoalide, 7,7-dimethyl-5,8-eicosadienoic acid, and p-bromophenacyl bromide. J Biol Chem 1989; 264: 8520-8.
165. Monti MC, Casapullo A, Cavasotto CN, Napolitano A, Riccio R. Scalaradial, a dialdehyde-containing marine metabolite that causes an unexpected noncovalent PLA2 Inactivation. Chembiochem 2007; 8: 1585-91.
166. Hyun PK, Kun HS, Hyeun WC, Sam SK. Anti-inflammatory Plant Flavonoids and Cellular Action Mechanisms. J Pharmacol Sci 2004; 96: 229-45.
167. Al-Ashaal HA, El-Sheltawy ST. Antioxidant capacity of hesperidin from citrus peel using electron spin resonance and cytotoxic activity against human carcinoma cell lines. Pharm Biol 2011; 49: 276-82.
168. 2 inhibitor from Cordia verbenacea (Boraginaceae): antiserum action potentiation and molecular interaction. Toxicon 2005; 46: 318-27.
169. 2 inhibition. PLoS One 2011; 61-11.e28521.
170. Sharmila R, Manoharan S. Anti-tumor activity of rosmarinic acid in 7,12- dimethylbenz(a)anthracene (DMBA) induced skin carcinogenesis in Swiss albino mice. Indian J Exp Biol 2012; 50: 187-94.
171. Arham S, Muhammad S, Paul M, Glenda CG. Protective activity of medicinal plants and their isolated compounds against the toxic effects from the venom of Naja (cobra) species. J Ethnopharmacol 2014; 157: 222-7.
172. Mohammad S. Lupeol, A novel anti-inflammatory and anti-cancer dietary triterpene. Cancer Lett 2009; 285: 109-15.
173. DaSilva ML, Marcussi S, Fernandes RS, et al. Anti-snake venom activities of extracts and fractions from callus cultures of Sapindus saponaria. Pharm Biol 2012; 50: 366-75.
174. Albert AB, Savarimuthu I, Gabriel MP, Khalid SAN. Chemopre-ventive potential of β -Sitosterol in experimental colon cancer model – an in vitro and in vivo study. BMC Complement Altern Med 2010; 10: 24.
175. Tirtha G, Tapan KM, Jagadish S. Evaluation of antitumor activity of stigmasterol, a constituent isolated from Bacopa monnieri Linn. aerial parts against Ehrlich Ascites Carcinoma in mice. Orient Pharm Exp Med 2011; 11: 41-9.
176. Jin MG, Min W, La PL, et al. Ergosterol peroxides as phospholipase A2 inhibitors from the fungus Lactarius hatsudake. Phy-tomedicine 2007; 14: 821-4.
177. Kim DH, Sung JJ, Sik C, et al. Ergosterol peroxide from flowers of erigeron annuus L. as an anti-atherosclerosis agent. Arch Pharm Res 2005; 28: 541-5.
178. Kobori, M.; Yoshida, M.; Ohnishi-Kameyama, M.; Shinmoto, H. Ergosterol peroxide from an edible mushroom suppresses inflammatory responses in RAW264.7 macrophages and growth of HT29 colon adenocarcinoma cells. Br J Pharmacol 2007; 150: 209-19.
179. Thaisa FSD, Magui AV, Diana NC, Eládio FS, Valéria LT, André LF. Effect of diterpenes isolated of the marine Alga Canistrocarpus cervicornis against some toxic effects of the venom of the Bothrops jararaca snake. Molecules 2015; 20: 3515-26.
180. Domingos, TFS, Vallim MA, Carvalho C, et al. Anti-snake venom effect of secodolastane diterpenes isolated from Brazilian marine brown alga Canistrocarpus cervicornis against Lachesis muta venom. Rev Bras Farmacogn 2011; 21: 234-8.
181. Chatterjee, I, Chakravarty AK, Gomes A. Daboia russellii and Naja kaouthia venom neutralization by lupeol acetate isolated from the root extract of Indian sarsaparilla Hemidesmus indicus R.Br. J Ethnopharmacol 2006; 106: 38-43.
182. Saifullahi U, Ahmed A, Hajara I, Balarabe AS, October N. Isolation of phospholipase A2 inhibitor from Cryptolepis oblongifolia (Meins) Schltr. J Nat Sci Res 2014; 4: 63-7.
183. Davidson FF, Hajdu J, Dennis EA. 1-Stearyl, 2-stearoylaminodeoxy phosphatidylcholine, a potent reversible inhibitor of phospholipase A2. Biochem. Biophys. Research Commu 1986; 137: 587-92.
184. Gelb MH. Fluoro ketone phospholipid analogs: new inhibitors of phospholipase A2. J Am Chem Soc 1986; 108: 3146-7.
185. Sun B, Zhang X, Talathi S, Cummings BS. Inhibition of Ca2+-independent phospholipase A2 decreases prostate cancer cell growth by p53-dependent and independent mechanisms. J Pharmacol Exp Ther 2008; 326: 59-68.
186. 2 with paclitaxel is highly effective in blocking ovarian cancer development. Am J Pathol 2011; 179: 452-61.
187. Tramposch, KM, Chilton FH, Stanely PL, et al. Inhibitor of phospholipase A2 blocks eicosanoid and platelet activating factor biosynthesis and has topical anti-inflammatory activity. J Pharm Exp Ther 1994: 271: 852-9.
188. Burke JR, Gregor KR, Tramposch KM. Mechanism of inhibition of human nonpancreatic secreted phospholipase A2 by the anti-inflammatory agent BMS-181162. J Biol Chem 1995; 270: 274-80.
189. Reid RC. Inhibitors of secretory phospholipase A2 group IIA. Curr Med Chem 2005; 12: 3011-26.
190. Tadimeti R, Chengzhi Z. Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2. U.S. Patent 20,110,306,552, December 15, 2011.
191. Tadimeti R, Chengzhi Z. Quinolone inhibitors of lipoprotein-associated phospholipase A2. U.S. Patent 20,110,136,861, June 9, 2011.
192. Kokotos G, Feuerherm AJ, Barbayianni E, et al. Inhibition of group IVA cytosolic phospholipase A2 by thiazolyl ketones in vitro, ex vivo, and in vivo. J Med Chem 2014; 57: 7523-35.
193. Marshall LA, Hall RH, Winkler JD, et al. SB 203347, an inhibitor of 14 kDa phospholipase A2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine endotoxin shock. J Pharmacol Exp Ther 1995; 274: 1254-62.
194. Thimmegowda NR, Dharmappa, KK, Ananda KCS, et al. Synthesis and evaluation of tricyclic dipyrido diazepinone derivatives as inhibitors of secretory phospholipase A2 with anti-inflammatory activity. Curr Top Med Chem 2007; 7: 811-20.
195. Schevitz RW, Bach NJ, Carlson DG, et al. Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nat Struct Biol 1995; 2: 458-65.
196. Abraham E, Naum C, Bandi V, et al. Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure. Crit Care Med 2003; 31: 718-28.
197. Bradley JD, Dmitrienko AA, Kivitz AJ et al. A randomized, dou-ble-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J Rheumatol 2005; 32: 417-23.
198. http://clinicaltrials.gov, Identifier: NCT00743925
199. Nicholls SJ, Kastelein JP, Schwartz GG, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: The VISTA-16 randomized clinical trial. JAMA 2014; 311: 252-262.
200. Lee KL, Foley, MA, Chen, L, et al. Discovery of Ecopladib, an indole inhibitor of cytosolic phospholipase A2alpha. J Med Chem 2007; 50: 1380-400.
201. McKew JC, Lee KL, Shen MW, et al. Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl] amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib. J Med Chem 2008; 51: 3388-413.
202. Clinical trials. A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The Knee. Available from: http://clinicaltrials.gov/, Identifier: NCT00 396955
203. Thotala D, Craft JM, Ferraro DJ, et al. Cytosolic phospholipasea2 inhibition with PLA-695 radiosensitizes tumors in lung cancer animal models. PLoS One 2013; 8: e69688.
204. Kirincich SJ, Xiang J, Green N, et al. Benzhydrylquinazolinedi-ones: novel cytosolic phospholipase A2alpha inhibitors with improved physicochemical properties. Bioorg Med Chem 2009; 17: 4383-405.
205. Tomoo T, Nakatsuka T, Katayama T, et al. Design, synthesis, and biological evaluation of 3-(1-Aryl-1H-indol-5-yl)propanoic acids as new indole-based cytosolic phospholipase A2α inhibitors. J Med Chem 2014; 57: 7244-62.
206. Boyd HF, Fell SC, Flynn ST, et al. N-1 substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2. Bioorg Med Chem Lett 2000; 10: 2557-61.
207. Blackie JA, Bloomer JC, Brown MJ, et al. The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2. Bioorg Med Chem Lett 2003; 13: 1067-70.
208. Clinical trials. A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema. Available from: http://ClinicalTrials.gov Identifier:NCT01506895
209. Clinical trials. The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial (STABILITY). Available from: http://ClinicalTrials.gov Identifier: NCT00799903.
210. O’Donoghue ML. Effect of darapladib on major coronary events after an acute coronary syndrome The SOLID-TIMI 52 randomized clinical trial. JAMA 2014; 312: 1006-15.
211. Clinical trials. Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans AIM III. Available from: http://Clinical Trials.gov Identifier: NCT01067339.
212. 2 inhibitors and the unexpected discovery of highly potent quaternary ammonium salts. Bioorg Med Chem Lett 2013; 23: 1187-92.
213. 2 inhibitors. Bioorg Med Chem Lett 2013; 23: 2897-901.
214. Syed NAB, Xin Z, Ibrahim J, Hai-Liang Z, Muhammad WA, Vijay HM. Synthesis, molecular modeling, and biological evaluation of novel 1, 3-Diphenyl-2-propen-1-one based pyrazolines as anti-inflammatory agents. Chem Biol Drug Des 2015; 85(6): 729-42.
215. John EB, Edward AD. Phospholipase A2 Biochemistry. Cardiovasc Drugs Ther 2009; 23: 49-59.
216. Stephens JWW, John LWS, Myers W. The action of cobra poison on the blood: A contribution to the study of passive immunity. J Pathol Bacteriol 1898; 5 (3): 279-301
217. 2-s from Vipera lebetina, Vipera berus berus and Naja naja oxiana Venom with Platelets, Bacterial and Cancer Cells. Toxins 2013; 5(2): 203-23.
218. Lambeau G, Gelb MH. Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem 2008; 77: 495-520.
219. Suzuki N, Ishizaki J, Yokota Y, et al. Structures, enzymatic properties, and expression of novel human and mouse secretory phospholipase A(2)s. J Biol Chem 2000; 275: 5785-93.
220. Starkl P, Marichal T, Galli, SJ. PLA2G3 promotes mast cell maturation and function. Nat Immunol 2013; 14: 527-9.
221. Meliton AY, Muñoz NM, Meliton LN, Birukova AA, Leff AR, Birukov KG. Mechanical induction of group V phospholipase A(2) causes lung inflammation and acute lung injury. Am J Physiol Lung Cell Mol Physiol 2013; 304: 689-700.
222. Murakami M, Masuda S, Shimbara S, et al. Cellular arachidonate-releasing function of novel classes of secretory phospholipase A2s (groups III and XII). J Biol Chem 2003; 278: 10657-67.
223. Guan M, Qu L, Tan W, Chen L, Wong, CW. Hepatocyte nuclear factor-4 alpha regulates liver triglyceride metabolism in part through secreted phospholipase A₂ GXIIB. Hepatology 2011; 53: 458-66.
224. Ghosh M, Loper R, Ghomashchi F, et al. Function, activity, and membrane targeting of cytosolic phospholipase A(2)zeta in mouse lung fibroblasts. J Biol Chem 2007; 282: 11676-86.
225. Michelle V, Winstead JB, Edward AD. Calcium-independent phospholipase A2: structure and function. Biochimica et Biophysica Acta 2000; 1488: 28-39.
226. Mancuso DJ, Jenkins CM, Gross RW. The genomic organization, complete mRNA sequence, cloning, and expression of a novel human intracellular membrane-associated calcium-independent phospholipase A2. J Biol Chem 2000; 275: 9937-45.
227. Wilensky L, Shi Y, Mohler IER, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008; 14: 1059-66.
228. Jaworski K, Ahmadian M, Duncan RE, et al. AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency. Nat Med 2009; 15: 159-68.
229. Lee JG, Lee SH, Park DW, et al. Toll-like receptor 9-stimulated monocyte chemoattractant protein-1 is mediated via JNK-cytosolic phospholipase A2-ROS signaling. Cell Signal 2008; 20(1): 105-11.